Can male vaccination reduce the burden of human papillomavirus-related disease in the United States?

Viral Immunology

Volumn 25, Issue 3, 2012, Pages 174-186

  Low, Garren M I ^a,c   Attiga, Yasser S ^b,c   Garg, Gaurav ^c   Schlegal, Richard ^c   Gallicano, G Ian ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; INFECTION PREVENTION; MALE; MALE HOMOSEXUAL; PAPILLOMAVIRUS INFECTION; PATIENT EDUCATION; PRIMARY PREVENTION; QUALITY ADJUSTED LIFE YEAR; REVIEW; SCREENING; UTERINE CERVIX CANCER; VACCINATION;

ADOLESCENT; ADULT; CHILD; CLINICAL TRIALS AS TOPIC; FEMALE; HOMOSEXUALITY, MALE; HUMANS; MALE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINATION; YOUNG ADULT;

EID: 84862248684     PISSN: 08828245     EISSN: 15578976     Source Type: Journal    
DOI: 10.1089/vim.2011.0083     Document Type: Review

References (97)

1. Stratton KR, Durch JS, and Lawrence RS, eds.: National Academy Press, Washington, DC, pp. 213-222. Accessed at http://www.iom.edu/report.asp?id-5648.
2. Armstrong EP: Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Managed Care Pharmacy 2010;16:217-230.
3. Ault KA, and Future II Study Group: Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials Lancet 2007;369:1861-1868. (Pubitemid 46829356)
4. Bauch CT, Li M, Chapman GC, and Galvani AP: Adherence to cervical screening in the era of human papillomavirus vaccination: how low is too low? Lancet Infect Dis 2010;10: 133-137.
5. Bergeron C, Largeron N, McAllister R, Mathevet P, and Remy V: Cost-effectiveness analysis of the introduction of a quadrivalent human papillomavirus vaccine in France. Int J Technol Assess Health Care 2008;24:10-19. (Pubitemid 351158538)
6. Biellik R, Levin C, Mugisha E, LaMontagne DS, Bingham A, Kaipilyawar S, and Gandhi S: Health systems and immunization financing for human papillomavirus vaccine introduction in low-resource settings. Vaccine 2009;27:6203-6209.
7. Bogaards JA, Coupe VM, Xiridou M, Meijer CJ, Wallinga J, and Berkhof J: Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011;22:505-515.
8. Broomall EM, Reynolds SM, and Jacobson RM: Epidemiology, clinical manifestations, and recent advances in vaccination against human papillomavirus. Postgrad Med 2010; 122:121-129.
9. Brotherton JM, Fridman M, May CL, Chappell G, Saville AM, and Gertig DM: Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet 2011;377:2085-2092.
10. Bulkmans N, Berkhof J, Rozendaal L, et al.: Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370:1764.
11. Bush M: HPV vaccine for MSM. Aust Nurs J 2008;16:33.
12. Castle PE, and Scarinci I: Should HPV vaccine be given to men? BMJ 2009;339:b4127.
13. Centers for Disease Control and Prevention (CDC): National, state, and local area vaccination coverage among adolescents aged 13-17 years-United States, 2008. MMWR Morb Mortal Wkly Rep 2009;58:997-1001.
14. Centers for Disease Control and Prevention (CDC): CDC Health Concerns Following HPV Vaccine Safety, 2010.
15. Centers for Disease Control and Prevention (CDC): Genital HPV Infection-CDC Fact Sheet, 2009. 4-7-2011.
16. Chaturvedi AK, Engels EA, Pfeiffer RM, et al.: Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J. Clin Oncol 2011;29:4294-4301.
17. Chekola MM: Outing, truth-telling, and the shame of the closet. J Homosex 1994;27:67-90.
18. Chesson HW, Ekwueme DU, Saraiya M, Dunne EF, and Markowitz LE: The cost-effectiveness of male HPV vaccination in the United States. Vaccine 2011;29:8443-8450.
19. Collins S, Mazloomzadeh S, Winter H, Blomfield P, Bailey A, Young LS, and Woodman CB: High incidence of cervical human papillomavirus infection in women during their first sexual relationship. BJOG 2002;109:96-98.
20. Dasbach EJ: Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease. Epidemiol Rev 2006; 28:88-100.
21. Dasbach EJ, Insinga RP, Yang YC, Pwu RF, Lac C, and Elbasha EH: The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Taiwan. Asian Pac J Cancer Prev 2008;9:459-466.
22. Donovan B, Franklin N, Guy R, et al.: Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011;11:39-44.
23. Edwin AK: Is routine human papillomavirus vaccination an option for Ghana? Ghana Med. J 2010;44:70-75.
24. Eichler HG, Kong SX, Gerth WC, Mavros P, and Jonsson B: Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health 2004;7:518-528. (Pubitemid 39390832)
25. Elbasha EH, and Dasbach EJ: Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010;28:6858-6867.
26. Franceschi S, Denny L, Irwin KL, et al.: Eurogin 2010 roadmap on cervical cancer prevention. Int J Cancer 2011;128: 2765-2774.
27. Gao L: Anal HPV infection in HIV-positive men who have sex with men from China. PloS One 2010;5:e15256.
28. Garland SM: Can cervical cancer be eradicated by prophylactic HPV vaccination? Challenges to vaccine implementation. Indian J Med Res 2009;130:311-321.
29. Garland SM: Prevention strategies against human papillomavirus in males. Gynecol Oncol 2010;117:S20-S25.
30. Garland SM, Hernandez-Avila M, Wheeler CM, et al.: Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases N Engl J Med 2007;356:1928-1943. (Pubitemid 46740303)
31. Giuliano AR: Human papillomavirus vaccination in males. Gynecol Oncol 2007;107:S24-S26.
32. Giuliano AR, Palefsky JM, Goldstone S, et al.: Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med 2011;364:401-411.
33. GlaxoSmithKline Vaccine HPV-007 Study Group, et al.: Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Lancet 2009;374:1975-1985.
34. Goldie SJ, O'Shea M, Diaz M, and Kim SY: Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications. Reprod Health Matters 2008;16:86-96.
35. Halkitis PN: Sexual behaviors of adolescent emerging and young adult men who have sex with men ages 13-29 in New York City. J Acquir Immune Defic Syndr 2011;56:285-291.
36. Henderson L, Clements A, Damery S, Wilkinson C, Austoker J, Wilson S, and on behalf of the HPV Core Messages Writing Group: 'A false sense of security'? Understanding the role of the HPV vaccine on future cervical screening behaviour: a qualitative study of UK parents and girls of vaccination age. J Med Screen 2011;18:41-45.
37. Hibbitts S: Should boys receive the human papillomavirus vaccine? Yes. BMJ 2009;339:b4928. doi:b4928.
38. Horn L, Howard C, Waller J, and Ferris DG: Opinions of parents about school-entry mandates for the human papillomavirus vaccine. J Low Genit Tract Dis 2010;14:43-48.
39. Hu D, and Goldie S: The economic burden of noncervical human papillomavirus disease in the United States. Am J Obstet Gynecol 2008;198:500.e1-500.e7.
40. Hutton S, and Finlay F: Allaying parental concerns about the human papillomavirus vaccine. Paediatr Nurs 2009;21: 20-23.
41. Insignia RP, Liaw K, Johnson LG, and Madeleine MM: A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev 2008;17:1611-1622.
42. Jin F, Stein AN, Conway EL, et al.: Trends in anal cancer in Australia, 1982-2005. Vaccine 2011;29:2322-2327.
43. Kang M, Skinner R, and Usherwood T: Interventions for young people in Australia to reduce HIV and sexually transmissible infections: a systematic review. Sex Health 2010;7:107-128.
44. Kawana K, Yasugi T, and Taketani Y: Human papillomavirus vaccines: current issues & future. Indian J Med Res 2009;130:341-347.
45. Kim JJ: Targeted human papillomavirus vaccination of men who have sex with men in the USA: a cost-effectiveness modelling analysis. Lancet Infect Dis 2010;10:845-852.
46. Kim JJ, and Goldie SJ: Health and economic implications of HPV vaccination in the United States. N Engl J Med 2008; 359:821-832.
47. Kim JJ, and Goldie SJ: Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 2009;339:b3884.
48. Kitchener HC, Gilham C, Sargent A, et al.: A comparison of HPV DNA testing and liquid based cytology over three rounds of primary cervical screening: Extended follow up in the ARTISTIC trial. Eur J Cancer 2011, In Press.
49. Kjaer SK, Sigurdsson K, Iversen OE, et al.: A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila Pa) 2009;2:868-878.
50. Klug SJ, Hukelmann M, and Blettner M: Knowledge about infection with human papillomavirus: a systematic review. Prev Med 2008;46:87-98. (Pubitemid 351163310)
51. Korodi Z, Dillner J, Jellum E, et al.: Human papillomavirus 16, 18, and 33 infections and risk of prostate cancer: a Nordic nested case-control study. Cancer Epidemiol Biomarkers Prev 2005;14:2952-2955. (Pubitemid 43068830)
52. Kreuter A, and Wieland U: Human papillomavirus-associated diseases in HIV-infected men who have sex with men. Curr Opin Infect Dis 2009;22:109-114.
53. Kwan TT, Tam KF, Lee PW, Chan KK, and Ngan HY: The effect of school-based cervical cancer education on perceptions towards human papillomavirus vaccination among Hong Kong Chinese adolescent girls. Patient Educ Couns 2010.
54. Lazcano-Ponce E, and Allen-Leigh B: Innovation in cervical cancer prevention and control in Mexico. Arch Med Res 2009;40:486-492.
55. Lee Mortensen G: Drivers and barriers to acceptance of human- papillomavirus vaccination among young women: a qualitative and quantitative study. BMC Public Health 2010; 10:68.
56. Lee VJ, Tay SK, Teoh YL, and Tok MY: Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health 2011;11:203.
57. Munoz N, Manalastas R Jr, Pitisuttithum P, et al.: Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009;373:1949-1957.
58. Naucler P, Ryd W, Tömberg S, et al.: Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-1597. (Pubitemid 47598401)
59. Naucler P, Ryd W, Tömberg S, et al.: HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer 2007;97:129-132. (Pubitemid 47012098)
60. Nyitray AG, Carvalho da Silva RJ, Baggio ML, et al.: Age-specific prevalence of and risk factors for anal human papillomavirus (HPV) among men who have sex with women and men who have sex with men: the HPV in men (HIM) study. J Infect Dis 2011;203:49-57.
61. Okolo C, Franceschi S, Adewole I, et al.: Human papillomavirus infection in women with and without cervical cancer in Ibadan, Nigeria. Infectious Agents Cancer 2010;5:24.
62. Olsson SE, Kjaer SK, Sigurdsson K, et al.: Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin 2009;5:696-704.
63. Othman NH, and Rebolj M: Challenges to cervical screening in a developing country: The case of Malaysia. Asian Pac J Cancer Prev 2009;10:747-752.
64. Paavonen J, Naud P, Salmeron J, et al.: Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374:301-314.
65. Palefsky JM: Human papillomavirus-related disease in men: not just a women's issue. J Adolesc Health 2010;46:S12-S19.
66. Palefsky JM, Giuliano AR, Goldstone S, et al.: HPV Vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011;365:1576-1585.
67. Petaja T, Keranen H, Karppa T, et al.: Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health 2009;44:33-40.
68. Qiao Y, Sellors JW, Eder PS, et al.: A new HPV-DNA test for cervical-cancer screening in developing regions: a cross-sectional study of clinical accuracy in rural China. Lancet Oncol 2008;9:929-936.
69. Ramanakumar AV, Gonclaves O, Richardson H, Tellier P, Ferenczy A, Coutlée F, and Franco EL: Human papillomavirus (HPV) types 16, 18, 31, 45 DNA loads and HPV-16 integration in persistent and transient infections in young women. BMC Infect Dis 2010;10:326.
70. Read TRH, Hocking JS, Chen MY, Donovan B, Bradshaw CS, and Fairley CK: The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sex Transm Infect 2011;87:544-547.
71. Reiter PL, Brewer NT, McRee AL, Gilbert P, and Smith JS: Acceptability of HPV vaccine among a national sample of gay and bisexual men Sex Transm Dis 2010;37:197-203.
72. Robbins SC, Bernard D, McCaffery K, Brotherton J, Garland S, and Skinner SR: "Is cancer contagious?": Australian adolescent girls and their parents: Making the most of limited information about HPV and HPV vaccination. Vaccine 2010.
73. Roberts JN: Clinical Review of Biologics License Application Supplement STN #125126/1297.0-male indication for GAR-DASIL, 2009.
74. Ronco G, Giorgi-Rossi P, Carozzi F, et al.: Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol.
75. Rothman SM, and Rothman DJ: Marketing HPV vaccine: implications for adolescent health and medical professionalism. JAMA 2009;302:781-786.
76. Sahasrabuddhe VV, Bhosale RA, Kavatkar AN, et al.: Comparison of visual inspection with acetic acid (VIA) and cervical cytology to detect high grade cervical neoplasia among HIV-infected women in India. Int J Cancer 2011.
77. Sankaranarayanan R, Nene BM, Shastri SS, et al.: HPV screening for cervical cancer in rural India. N Engl J Med 2009;360:1385-1394.
78. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, and Castle PE: Human papillomavirus testing in the prevention of cervical cancer. J. Natl. Cancer Inst 2011;203: 368-383.
79. Schiffman M: Integration of human papillomavirus vaccination, cytology, and human papillomavirus testing. Cancer 2007;111:145-153.
80. Schiffman M, and Castle PE: The promise of global cervical-cancer prevention. N Engl J Med 2005;353:2101-2104. (Pubitemid 41653100)
81. Schwarz TF, Spaczynski M, Schneider A, et al.: Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009;27:581-587.
82. Shukla S, Bharti AC, Mahata S, Hussain S, Kumar R, Hedau S, and Das BC: Infection of human papillomaviruses in cancers of different human organ sites. Indian J Med Res 2009;130:222-233.
83. Sikora AG, Morris LG, and Sturgis EM: Bidirectional association of anogenital and oral cavity/pharyngeal carcinomas in men. Arch Otolaryngol Head Neck Surg 2009;135: 402-405.
84. Silversides A: Cost of HPV vaccine is prohibitive in developing world, Nobel winner says. CMAJ 2009;181:E288.
85. Smith EM, Ritchie JM, Summersgill KF, et al.: Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004;108:766-772. (Pubitemid 38076410)
86. Smith MA, Canfell K, Brotherton JM, Lew JB, and Barnabas RV: The predicted impact of vaccination on human papillomavirus infections in Australia. Int J Cancer 2008;123: 1854-1863.
87. Sourvinos G, Mammas IN, and Spandidos DA: Oral human papillomavirus (HPV) infection-are there implications for HPV vaccination? J Infect Dis 2010;201:478; author reply 478-479.
88. Sroczynski G, Schnell-Inderst P, Mühlberger N, et al.: Decision- analytic modeling to evaluate the long-term effectiveness and cost-effectiveness of HPV-DNA testing in primary cervical cancer screening in Germany. GMS Health Technol Assess 2010;6:Doc05.
89. Talbot TR: Improving rates of influenza vaccination among healthcare workers: educate; motivate; mandate? Infect Control Hosp Epidemiol 2008;29:107-110.
90. Tsu VD: Overcoming barriers and ensuring access to HPV vaccines in low-income countries. Am J Law Med 2009;35: 401-413.
91. Villa LL, Costa RL, Petta CA, et al.: High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-1466. (Pubitemid 44863348)
92. Viner J: The utility concept in value theory and its critics. J Political Economy 1925;33:638-659.
93. Walboomers JM, Jacobs MV, Manos MM, et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19. (Pubitemid 29406813)
94. Wang S: Impact of human papillomavirus-related lesions on quality of life: a multicenter hospital-based study of women in Mainland China. Int J Gynecol Cancer 2011;21:182-188.
95. Watson M, Saraiya M, Ahmed F, Cardinez CJ, Reichman ME, Weir HK, and Richards TB: Using population-based cancer registry data to assess the burden of human papillomavirus-associated cancers in the United States: overview of methods. Cancer. 2008;113:2841-2854.
96. Wong CA, Saraiya M, Hariri S, et al.: Approaches to monitoring biological outcomes for HPV vaccination: challenges of early adopter countries. Vaccine 2011;29:878-885.
97. World Health Organization (WHO): Human papillomaviruses. IARC Monogr Eval Carcinog. Risks Hum 2007;90: 1-636.